These 2 TSX Stocks Will Report Their Earnings Next Week: Should You Buy?

Amid improved investors’ sentiments, should you buy Aurora Cannabis and Air Canada ahead of their earnings?

| More on:
edit Businessman using calculator next to laptop

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Amid the optimism over the new stimulus package in the United States and the improvement in economic recovery, the S&P/TSX Composite Index hit a new all-time of 18,072.17 yesterday before closing at 18,041.97, representing an increase of 3.5% for this year. Meanwhile, Aurora Cannabis (TSX:ACB)(NYSE:ACB) and Air Canada (TSX:AC) will report their quarterly earnings next week. Should you buy these stocks ahead of their earnings? Let’s see.

Aurora Cannabis

The optimism in the cannabis space amid the expansion of addressable market due to increased legalization and Democrats taking over the control of both Senate and House appear to have led Aurora Cannabis’s stock to rise 212.3% since the beginning of November.

In its first quarter that ended on September 30, the company had posted revenues of $67.8 million — a slight increase from $67.5 million in the previous year’s quarter. Its adjusted EBITDA losses were at $57.9 million. However, removing restructuring payments of $47.4 million, its adjusted EBITDA losses stood at $10.5 million. Meanwhile, the company will report its second-quarter earnings after the market closes on February 11. The management expects its adjusted EBITDA to improve sequentially.

The expansion of its product offerings and higher retail store openings in major Canadian markets could drive Aurora Cannabis’s revenue in the second quarter. Further, the closure of excess production facilities, scaling down of headcount, and lower SG&A expenses could improve the company’s EBITDA. The company’s financial position also looks stable, with its cash standing at $450 million as of December 15.

Despite cannabis stocks witnessing strong buying in the last couple of months, I would wait until Aurora Cannabis’s second-quarter earnings to make my investment decision on the stock. The company’s performance in recent quarters has failed to increase investors’ confidence. Further, analysts are also less optimistic about the stock. Of the 17 analysts covering Aurora Cannabis, 13 have given a “hold” rating, while the remaining four analysts have issued a “sell” rating.

Air Canada

The pandemic-infused travel restrictions have severely dented the passenger airline stocks, including Air Canada. Amid the subdued passenger demand, the company carried 88% lesser passenger in the third quarter compared to its previous year’s quarter. Its top line declined by 86%, while its adjusted EBITDA fell by 62.4%. Further, the company’s net cash burn for the quarter stood at $818 million, or $9 million per day, which was better than the management’s expectations. However, the management had projected its net cash burn to increase in the fourth quarter to be in the range of $1.1 billion to $1.3 billion.

However, with $8.19 billion in liquidity, Air Canada is well equipped to ride out this crisis. Further, the company has taken several cost-reduction initiatives, such as slashing its headcount and lowered its operating capacity to 20% of the previous year to reduce its losses. Further, the company’s cargo business is growing since its launch in March 2020. The company is adding more cargo-only flights to meet the increased demand.

Meanwhile, Air Canada will report its fourth-quarter earnings before the market opens on February 12. Analysts expect the company’s revenue to come in at $1.13 billion, representing a sequential improvement from $1.01 billion in the third quarter. Its EBITDA losses could also improve from $974.8 million to $641.3 million. Of the 18 analysts that cover Air Canada, 13 analysts have issued a “buy” rating, while four have given a “hold” rating, and the remaining analyst has given a “sell” rating.

With travel restrictions still in place, I am not hoping much from Air Canada’s fourth-quarter results. However, the vaccine’s widespread distribution could prompt governments to ease travel restrictions and increase travelers’ confidence, boosting air travel. So, I believe investors with two to three years of an investment time frame could buy the stock for superior returns.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »